When it legalized recreational cannabis in October 2018, Canada became the first G7 country to do so nationwide. The change was framed as a public-health and public-safety reform rather than a commercial one. Five years on, the legalisation of cannabis has reshaped law enforcement, consumer behaviour, public health policy, and a multibillion-dollar industry.
But has it functioned as it should?
The answer is complex. While Canada got some of the basic elements right, deep-seated structural and policy flaws continue to impede full success of legalization.
What Canada Got Right
1. Replacing an Unregulated Market with a Safer Legal One
One of the key objectives of the Cannabis Act was to reduce the harms associated with an illegal, unregulated market. On this front, Canada has measurable progress.
Federal data shows that most of the cannabis consumed in Canada is now coming from legal sources, whereas in the period before 2018, near-total reliance was placed on illicit markets. Legal products are subject to strict quality controls, testing standards, and labelling requirements that reduce risks related to contamination or unknown potency.
That shift has not only improved consumer safety but brought a certain amount of transparency to THC and CBD content that was never provided through the illegal market.
2. Strong Focus on Public Health and the Protection of Youth
Canada’s cannabis framework had consciously taken away the primacy accorded to commercial growth and given pride of place to public health. Advertising restrictions, plain packaging rules, and limits on branding were designed to prevent cannabis from being marketed like alcohol or tobacco.
Trends in the usage of youth would suggest that legalisation has not led to a dramatic upsurge in consumption by underage citizens-a fact that runs counter to perhaps the most common pre-legalisation fears. Education campaigns and age-gated retail access have played a role in this outcome.
This is an indication that while the consumption of youth is still an issue at hand, the data do not support the claim that legalisation legalised the sudden rise of consumption below underage.
3. Clear Separation between Medical and Recreational Access
Before 2018, Canada already had a medical cannabis framework in place; legalisation did not replace the system but preserved it. In fact, patients with medical authorisation can access cannabis through licensed producers. Many of these products have higher possession limits and specific formulations.
This separation has helped to legitimize the use of medical cannabis while allowing recreational policy to be informed by different public-health considerations.
What Canada Got Wrong
1. Excise Taxes That Punish Legal Producers
One of the most cited failures of Canada’s cannabis framework is its excise tax structure. Cannabis is taxed at a flat rate per gram or a percentage of price, whichever is higher. As wholesale prices came down, taxes often outpaced producer margins.
This has disproportionately hurt small and mid-sized licensed producers, and contributed to bankruptcies and market consolidations.
The whole debate is rendered moot in many cases because legal cannabis cannot compete with illicit products simply due to tax policies keeping prices artificially high.
2. The Illicit Market Did Not Disappear
Legal cannabis has increased its market share, but illegal cannabis has not been eradicated. Social sourcing, unlicensed dispensaries, and grey-market products continue to operate, especially in areas with limited legal access or high prices.
Indeed, government reporting recognizes that enforcement cannot be the complete answer to this problem alone, where legal products are not price competitive.
Legalization reduced harm but did not automatically dismantle entrenched informal supply networks.
3. Overregulation and Slow Adaptation
Producers and retailers often point out the regulatory rigidity that acts as an obstacle to innovation. Packaging rules, product approval timelines, and limited flexibility given for marketing-legal businesses have not been able to respond to consumer demand.
Recent regulatory changes have been designed to peel away some of the administrative burden, but critics say these reforms came too late for the many companies that had already exited the market.
4. Lack of Treatment for Those in Need of Medicinal Marijuana
Ironically, though, recreational legalization has only marginally improved access for medical patients. Many patients have indeed reported higher costs and much more limited insurance and administrative hurdles.
Consequently, some patients with medical authorization today purchase cannabis through recreational channels, which further blurs the separation of the two systems.
Five Years In: What Do We Know?
Canada’s experience shows that legalisation alone is not enough. Policy design matters just as much as the decision to legalise. Strong public-health controls, consumer safety standards, and legal access were clear successes. However, taxation policy, market flexibility, and patient access were under-estimated.
The ongoing statutory review of the Cannabis Act reflects the recognition that legalisation is a process, not an event. Tuning remains necessary to make the legal market viable and competitive, and one compatible with public health objectives.
Conclusion
Five years from Legalisation, the cannabis experiment in Canada cannot be termed a failure, yet neither can it be termed complete. The country succeeded in replacing prohibition with regulation, improving safety and transparency. At the same time, economic pressures, regulatory friction, and persistent illicit activity make clear the limits of the original framework.
For countries looking on at Canada as a case study, the lesson is clear: legalisation works best when regulation, taxation, and market realities evolve together.
